Similar to ALK, another oncogenic RTK, RET, also undergoes multiple distinct and recurrent gene rearrangements in human cancer, leading to the elimination of the extracellular and transmembrane domains from the various fusion oncoproteins (Kato et al., 2017). The gene discussed is RET; the disease is cancer.